Share

February 2015; 2 (1) EditorialOpen Access

MOG antibody-associated diseases

Markus Reindl, Kevin Rostasy
First published January 22, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000060
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
10818

Share

Article Information

vol. 2 no. 1 e60
DOI: 
https://doi.org/10.1212/NXI.0000000000000060
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • First Published January 22, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Markus Reindl, PhD and
    2. Kevin Rostasy, MD
  1. Markus Reindl, PhD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. PLOS ONE, academic editor, 2012-Current Medicinal Chemistry, editorial board, 2006-2012 Autoimmune Diseases, 2012-2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Dr. Reindl and Medical University of Innsbruck receive payments for antibody assays (AQP4 and antineuronal antibodies) and for AQP4 antibody validation experiments organized by Euroimmun.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Austrian Science Fund (FWF), grants W1206 and I916 Austrian Federal Ministry of Science grant ?BIG-WIG MS? Jubilaeumsfonds of the Austrian National Bank, grants 14158 and 15198

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Kevin Rostasy, MD
    3. Scientific Advisory Boards:

    1. Scientific adviser on Fingolimod project-Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Merck-Serono- Symposium speaker GNP annual meeting 2013, Innsbruck

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria; and Division of Pediatric Neurology (K.R.), Children's Hospital Datteln, University Witten/Herdecke, Datteln, Germany.
  1. Correspondence to Dr. Reindl: markus.reindl{at}i-med.ac.at

Article usage

Article usage: January 2015 to November 2023

AbstractFullPdfSource
Jan 201551171174Highwire
Feb 20151464066Highwire
Feb 201506942pmc
Mar 2015464627Highwire
Mar 201507032pmc
Apr 2015672531Highwire
Apr 201503616pmc
May 2015321720Highwire
May 201504112pmc
Jun 2015652416Highwire
Jun 201502610pmc
Jul 201530619Highwire
Jul 201503410pmc
Aug 2015492411Highwire
Aug 20150329pmc
Sep 2015216012Highwire
Sep 201506714pmc
Oct 20152288Highwire
Oct 201506221pmc
Nov 201525156Highwire
Nov 201508416pmc
Dec 201524146Highwire
Dec 201506217pmc
Jan 2016301110Highwire
Jan 2016014415pmc
Feb 201619811Highwire
Feb 201608316pmc
Mar 20161994Highwire
Mar 2016022733pmc
Apr 20161364Highwire
Apr 2016010225pmc
May 201623165Highwire
May 2016012128pmc
Jun 20163472Highwire
Jun 2016012722pmc
Jul 201620146Highwire
Jul 201608513pmc
Aug 2016381411Highwire
Aug 2016017326pmc
Sep 20161083Highwire
Sep 2016019224pmc
Oct 2016195115Highwire
Oct 201606513pmc
Nov 201616202Highwire
Nov 2016026426pmc
Dec 20168291Highwire
Dec 2016025128pmc
Jan 2017134112Highwire
Jan 2017029133pmc
Feb 2017143013Highwire
Feb 2017033025pmc
Mar 2017275116Highwire
Mar 2017040937pmc
Apr 201717416Highwire
Apr 201727291346pmc
May 2017144714Highwire
May 201737410482pmc
Jun 201710344Highwire
Jun 201736472556pmc
Jul 201716354Highwire
Jul 201752493569pmc
Aug 2017154113Highwire
Aug 201747451533pmc
Sep 2017144510Highwire
Sep 201758581685pmc
Oct 201712544Highwire
Oct 201762612706pmc
Nov 201718577Highwire
Nov 201766666782pmc
Dec 20175413Highwire
Jan 2018127810Highwire
Feb 2018125816Highwire
Mar 20188638Highwire
Apr 2018147411Highwire
Apr 2018689571101pmc
May 201851106Highwire
Jun 201814987Highwire
Jun 20187411181308pmc
Jul 2018121039Highwire
Aug 20188597Highwire
Aug 20187513881613pmc
Sep 201835010Highwire
Oct 2018147313Highwire
Nov 2018913017Highwire
Dec 2018614113Highwire
Jan 2019812615Highwire
Feb 2019713015Highwire
Mar 20191912711Highwire
Apr 2019189710Highwire
May 20191712115Highwire
Jun 201958316Highwire
Jul 2019411814Highwire
Aug 20191113913Highwire
Sep 2019312014Highwire
Oct 2019927318Highwire
Nov 20192239315Highwire
Dec 20191431914Highwire
Jan 20202313114Highwire
Feb 20201410712Highwire
Mar 20202111021Highwire
Apr 202079728Highwire
May 202029336Highwire
Jun 202087214Highwire
Jul 202045712Highwire
Aug 202076512Highwire
Sep 202076120Highwire
Oct 202035620Highwire
Nov 202075314Highwire
Dec 202064916Highwire
Jan 202176116Highwire
Feb 202155413Highwire
Mar 2021114719Highwire
Apr 2021143916Highwire
May 202111358Highwire
Jun 2021134824Highwire
Jul 202165624Highwire
Aug 202177117Highwire
Sep 20211338Highwire
Oct 202134123Highwire
Nov 202144524Highwire
Dec 20217379Highwire
Jan 20225347Highwire
Feb 2022103414Highwire
Mar 202244313Highwire
Apr 2022102619Highwire
May 202232814Highwire
Jun 20225289Highwire
Jul 20222317Highwire
Aug 20227489Highwire
Sep 202266318Highwire
Oct 202243813Highwire
Nov 202247728Highwire
Dec 202284221Highwire
Jan 202326120Highwire
Feb 20237478Highwire
Mar 20233909Highwire
Apr 202344321Highwire
May 202333111Highwire
Jun 20232256Highwire
Jul 202313012Highwire
Aug 20232428Highwire
Sep 20233296Highwire
Oct 20231216Highwire
Nov 20232312Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles